Stonewall Pharmaceutical Private Limited
Founded in 2018 and headquartered in Bihar, India.
2018 | Rohtas, Bihar (India) | Active
Stonewall Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -59.70%
- Profit Growth -106.27%
- Ebitda -115.81%
- Net Worth -71.88%
- Total Assets -33.77%
About Stonewall Pharmaceutical
Stonewall Pharmaceutical Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2018 (Six years and five months 29 days old ). Its registered office is in Rohtas, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Alok Kumar and Rohit Kumar serve as directors at the Company.
Company Details
- Location
Rohtas, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U93090BR2018PTC039064
- Company No.
039064
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2018
- Date of AGM
26 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Pharma
Who are the key members and board of directors at Stonewall Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alok Kumar  | Director | 01-Sep-2018 | Current |
| Rohit Kumar | Director | 01-Sep-2018 | Current |
Financial Performance of Stonewall Pharmaceutical.
Stonewall Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 59.7% decrease. The company also saw a substantial fall in profitability, with a 106.27% decrease in profit. The company's net worth observed a substantial decline by a decrease of 71.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stonewall Pharmaceutical?
Unlock access to Stonewall Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stonewall Pharmaceutical?
Unlock and access historical data on people associated with Stonewall Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stonewall Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stonewall Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
